Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.84 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 2/20 | 0.57 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19012034 | 1.00 | JAK3 (0.84) | JAK3HTR2CLCKDOT1LJAK2 | |
| SCHEMBL1948790 | 0.96 | JAK3 (0.91) | JAK3HTR2CLCKDOT1LJAK2 | |
| SCHEMBL10206799 | 0.94 | JAK3 (0.83) | JAK3HTR2CLCKDOT1LJAK2 | |
| SCHEMBL322821 | 0.93 | JAK3 (0.84) | JAK3HTR2CLCKDOT1L | |
| SCHEMBL1047971 | 0.93 | JAK3 (0.84) | JAK3HTR2CLCKDOT1L | |
| SCHEMBL24491026 | 0.92 | JAK3 (0.88) | JAK3HTR2CLCK | |
| SCHEMBL10207321 | 0.91 | JAK3 (1.00) | JAK3HTR2CLCKDOT1L | |
| SCHEMBL10206809 | 0.90 | JAK3 (0.93) | JAK3HTR2CLCK | |
| SCHEMBL19011824 | 0.90 | JAK3 (0.93) | JAK3HTR2CLCK | |
| SCHEMBL1048666 | 0.90 | JAK3 (0.80) | JAK3HTR2CLCKDOT1LJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022117075-A1 | AZACYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广州费米子科技有限责任公司 | 2022-06-09 | — | — | WO | disclosed |
| WO-2022117075-A1 | AZACYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 广州费米子科技有限责任公司 | 2022-06-09 | — | — | WO | disclosed |
| CN-114591321-A | Aza-and-cyclic compounds, method for the production thereof and use thereof | 广州费米子科技有限责任公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-3858349-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858349-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3181570-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181570-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-2460806-B1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8609647-B2 | Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof | JAPAN TOBACCO INC. (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2460806-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| EP-2460806-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | JAK3 899/4885HTR2C 3921/4885LCK 669/4885 |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NPR1 | JAK3 570/4885HTR2C 4394/4885LCK 542/4885 |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | JAK3 899/4885HTR2C 3921/4885LCK 669/4885 |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, NPR1 | JAK3 504/4885HTR2C 4329/4885LCK 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.